Nuzenio

Biopharma Dive Replimune

Biopharma Dive Replimune news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 2 publisher sources 100/100 entity strength

Latest news

Timeline

Fri, 07 Aug 2026 15:02:34 GMT‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - BioPharma Dive
Thu, 06 Aug 2026 21:16:19 GMTReplimune rebounds to win FDA approval of melanoma drug - BioPharma Dive
Tue, 04 Aug 2026 14:35:26 GMTJ&J pharma leader to retire; Krystal slumps on gene therapy miss - BioPharma Dive
Fri, 31 Jul 2026 15:18:11 GMTSanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs - BioPharma Dive
Thu, 30 Jul 2026 07:00:00 GMTReplimune melanoma drug wins support of FDA panel - BioPharma Dive
Wed, 29 Jul 2026 07:00:00 GMTFDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Biopharma Dive Replimune.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.